Virologically suppressed HIV On TDF/FTC/EFV CrCl more than 60 ml/min Dual antiretroviral therapy, dolutegravir, virologic outcome, renal outcome
Conditions
Interventions
Oral dolutegravir 50 mg per day plus lamivudine 300 mg per day,Oral fixed drug combination of TDF 300 mg per day, lamivudine 300 mg per day, and dolutegravir 50 mg per day
Active Comparator Drug,Active Comparator Drug
DTG/3TC,TDF/3TC/DTG
Sponsors
Mahasarakham University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: HIV-infected adults age of 18 years or more Receiving TDF/FTC/EFV Documented HIV VL < 50 copies/mL in the past 12 months
Exclusion criteria
Exclusion criteria: Pregnancy History of documented HIV drug resistance History of DTG hypersensitivity Estimated glomerular filtration rate < 60 ml/min Cirrhosis CTP B or C Currently on antituberculosis therapy Receiving metformin > 1000 mg/day If available, initial HIV VL > 500,000 copies/mL Positive HBsAg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate 24, 48 weeks ml/min/1.73 m2 | — |
Secondary
| Measure | Time frame |
|---|---|
| HIV viral load 24, 48 weeks copies per mL | — |
Countries
Thailand
Contacts
Public ContactSamadhi Patamatamkul
Faculty of Medicine, Mahasarakham University
Outcome results
None listed